Reactive arthritis following treatment with intravesical Bacillus Calmette-Guerin for papillary carcinoma of bladder

被引:0
作者
Singh, Yogesh Preet [1 ]
Roy, Debaditya [1 ]
Jois, Bhargavi [2 ]
Shetti, Mohit [3 ]
机构
[1] Manipal Hosp, Rheumatol, HAL Airport Rd, Bangalore, Karnataka, India
[2] Manipal Hosp, Nucl Med, HAL Airport Rd, Bangalore, Karnataka, India
[3] Manipal Hosp, Gastroenterol, HAL Airport Rd, Bangalore, Karnataka, India
关键词
Musculoskeletal and joint disorders; Drugs and medicines; Unwanted effects; adverse reactions; Rheumatology; Urological cancer; BCG THERAPY; CANCER;
D O I
10.1136/bcr-2022-249208
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
A man in his 60s developed reactive arthritis following treatment with intravesical Bacillus Calmette-Guerin (iBCG) for papillary carcinoma of bladder. Evaluation revealed leucocytosis and raised inflammatory markers. HLA B27 was positive. Based on the temporal relationship, it was attributed to BCG-related reactive arthritis. iBCG was stopped. Treatment with non-steroidal anti-inflammatory drugs (NSAIDS) and glucocorticoids were ineffective. Prolonged course of disease-modifying antirheumatic drugs (DMARDS) was required which aided in alleviation of symptoms and sustained remission. Intravesical BCG therapy is a treatment for bladder cancer. It is rarely associated with reactive arthritis, which responds to discontinuation of iBCG and treatment with NSAIDS and/or short-term glucocorticoids. iBCG-related reactive arthritis commonly has an acute/subacute course. Chronic arthritis as observed in our case requiring prolonged treatment with DMARDS is rare.
引用
收藏
页数:3
相关论文
共 8 条
  • [1] Reactive Arthritis following Bacillus Calmette-Guerin Therapy for Bladder Cancer: a Systematic Literature Review
    Ben Abdelghani, Kawther
    Nacef, Lilia
    Miladi, Saoussen
    Sellami, Meriem
    Ouenniche, Kmar
    Souabni, Leila
    Kassab, Selma
    Chekili, Selma
    Fazaa, Alia
    Laatar, Ahmed
    [J]. CURRENT RHEUMATOLOGY REPORTS, 2021, 23 (06)
  • [2] Reactive arthritis induced by intravesical BCG therapy for bladder cancer: our clinical experience and systematic review of the literature
    Bernini, Luigi
    Manzini, Carlo Umberto
    Giuggioli, Dilia
    Sebastiani, Marco
    Ferri, Clodoveo
    [J]. AUTOIMMUNITY REVIEWS, 2013, 12 (12) : 1150 - 1159
  • [3] Fazaa A, 2014, BMJ CASE REP
  • [4] Freixa Marta, 2020, Eur J Case Rep Intern Med, V7, P001448, DOI 10.12890/2020_001448
  • [5] Reactive arthritis: update 2018
    Garcia-Kutzbach, A.
    Chacon-Suchite, J.
    Garcia-Ferrer, H.
    Iraheta, I.
    [J]. CLINICAL RHEUMATOLOGY, 2018, 37 (04) : 869 - 874
  • [6] Nakagawa T, 2018, INT CANCER CONF J, V7, P148, DOI 10.1007/s13691-018-0342-1
  • [7] Frequency of reactive arthritis, uveitis, and conjunctivitis in Japanese patients with bladder cancer following intravesical BCG therapy: A 20 year, two-centre retrospective study
    Taniguchi, Yoshinori
    Nishikawa, Hirofumi
    Karashima, Takashi
    Yoshinaga, Yasuhiko
    Fujimoto, Shimpei
    Terada, Yoshio
    [J]. JOINT BONE SPINE, 2017, 84 (05) : 637 - 638
  • [8] Reactive arthritis following BCG immunotherapy for urinary bladder carcinoma: a systematic review
    Tinazzi, E
    Ficarra, V
    Simeoni, S
    Artibani, W
    Lunardi, C
    [J]. RHEUMATOLOGY INTERNATIONAL, 2006, 26 (06) : 481 - 488